SCHEMBL25587196

SCHEMBL25587196

Cc1cncc(Oc2ccc(N)cc2C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
VEGFA P15692 1/20 0.39
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
PPARG P37231 1/20 0.37
CARM1 Q86X55 2/20 0.36
PRMT6 Q96LA8 2/20 0.36
GCK P35557 2/20 0.35
TEAD4 Q15561 1/20 0.35
PDE10A Q9Y233 1/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696595 0.84 PPARG (0.51) VEGFAPPARGKDM4EGAA
SCHEMBL24570024 0.84 VEGFA (0.41) ALDH1A1VEGFAPPARG
SCHEMBL29888021 0.84 VEGFA (0.41) ALDH1A1VEGFAPPARG
SCHEMBL30354830 0.83 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2PPARGTEAD4PDE10A
SCHEMBL5570133 0.83 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2PPARGTEAD4PDE10A
SCHEMBL1446655 0.79 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2KDM4EMEN1LMNA
SCHEMBL29887935 0.79 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2KDM4EMEN1LMNA
SCHEMBL12851581 0.79 KDM4E (0.41) ALDH1A1SMN1; SMN2VEGFAPRMT5WDR77
SCHEMBL2992329 0.79 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TEAD4PDE10AKDM4E
SCHEMBL29764012 0.79 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2CARM1PRMT6TEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382923-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-11-30 US disclosed
US-20230159557-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159557-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, ERBB3, BRCA1 ALDH1A1 4139/4885SMN1; SMN2 1701/4885VEGFA 4031/4885
US-20230382923-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, ERBB3, BRCA1 ALDH1A1 4139/4885SMN1; SMN2 1701/4885VEGFA 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.